Abstract: The present invention provides a phosphoramidate compound comprising the structure (I) Formula (I) wherein: X comprises a monosaccharide group comprising the structure (II) or (III), 8 Formula (II), (III) B and B are independently selected from the group consisting of —O—, —CH2— and a bond, preferably —O—; R1 is selected from the group consisting of —H, protecting groups and monovalent hydrocarbon radicals; R2 and R3 are independently selected from the group consisting of —H and monovalent hydrocarbon radicals, or R2 and R3 together form an alkylene or heteroalkylene chain so as to provide, together with the C atom to which they are attached, a cyclic system; R4 is selected from the group consisting of —H and monovalent hydrocarbon radicals; R5-R12 are independently selected from the group consisting of —H, —OH, N3, halogen, —SH, —OR13, —SR13?, NHR14, —NR142 and group Formula (I) wherein B? is selected from the group consisting of —O—, —CH2— and a bond, preferably —O—; R1-R4 are independently selected and are

Abstract: The invention relates to novel recombinant substrates for aggrecanase. In one embodiment, this substrate comprises the signal sequence of CD5, the FLAG-epitope for M1 monoclonal antibody detection, the interglobular domain of human aggrecan, the hinge region of human IgG1, the CH2 region of human IgG1 and the CH3 region of human IgG1. DNA sequences encoding the recombinant substrate are also provided, as are vectors and host cells containing said DNA. Various methods are provided for: monitoring aggrecanase activity, detecting new enzymatic cleavage sites, purifying aggrecanase chromatographically, and cloning the aggrecanase cDNA, screening for aggrecanase inhibitors; and for monitoring the onset or progression of osteoarthritis. A diagnostic aid containing the recombinant substrate is also provided.

Abstract: The invention relates to novel recombinant substrates for aggrecanase. In one embodiment, this substrate comprises the signal sequence of CD5, the FLAG-epitope for M1 monoclonal antibody detection, the interglobular domain of human aggrecan, the hinge region of human IgG1, the CH2 region of human IgG1 and the CH3 region of human IgG1. DNA sequences encoding the recombinant substrate are also provided, as are vectors and host cells containing said DNA. Various methods are provided for: monitoring aggrecanase activity, detecting new enzymatic cleavage sites, purifying aggrecanase chromatographically, and cloning the aggrecanase cDNA, screening for aggrecanase inhibitors; and for monitoring the onset or progression of osteoarthritis. A diagnostic aid containing the recombinant substrate is also provided.